Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences

Diabetes, Obesity and Metabolism

Volumn 19, Issue 5, 2017, Pages 672-681

  Horowitz, Michael ^a   Aroda, Vanita R ^b   Han, Jenny ^c   Hardy, Elise ^d   Rayner, Chris K ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b MEDSTAR RESEARCH INSTITUTE   (United States)

^c Pharmapace Inc   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

adverse events; exenatide; gastrointestinal disorders; GLP 1 receptor agonists; liraglutide; type 2 diabetes

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INCRETIN; PEPTIDE; VENOM;

ADULT; ARTICLE; ASIAN; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX RATIO; WEIGHT REDUCTION; AGONISTS; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; GASTROINTESTINAL DISEASES; HYPERGLYCEMIA; HYPOGLYCEMIA; INTENTION TO TREAT ANALYSIS; METABOLISM; MULTICENTER STUDY; PATHOPHYSIOLOGY; PATIENT DROPOUT; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SELF REPORT; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE;

DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL DISEASES; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; INCIDENCE; INCRETINS; INTENTION TO TREAT ANALYSIS; LIRAGLUTIDE; MALE; NAUSEA; PATIENT DROPOUTS; PEPTIDES; RETROSPECTIVE STUDIES; SELF REPORT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; VENOMS; WEIGHT LOSS;

EID: 85013499523     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12872     Document Type: Article

References (34)

1. Sun F, Chai S, Yu K, et al. Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Technol Ther. 2015;17:35-42.
2. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004;117:77-88.
3. Thazhath SS, Marathe CS, Wu T, et al. The glucagon-like peptide 1 receptor agonist exenatide inhibits small intestinal motility, flow, transit, and absorption of glucose in healthy subjects and patients with type 2 diabetes: a randomized controlled trial. Diabetes. 2016;65:269-275.
4. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372:1240-1250.
5. Meier JJ, Rosenstock J, Hincelin-Méry A, et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care. 2015;38:1263-1273.
6. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47.
7. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96:1301-1310.
8. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381:117-124.
9. Ji L, Onishi Y, Ahn CW, et al. Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus. J Diabetes Invest. 2013;4:53-61.
10. Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med. 2001;161:1989-1996.
11. BYETTA (exenatide) injection [package insert]. Wilmington, DE: AstraZeneca; 2015.
12. VICTOZA (liraglutide) injection, for subcutaneous use [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; 2016.
13. BYDUREON (exenatide extended release) for injectable suspension [package insert]. Wilmington, DE: AstraZeneca; 2015.
14. TANZEUM (albiglutide) for injection, for subcutaneous use [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2015.
15. TRULICITY (dulaglutide) injection [package insert]. Indianapolis, IN: Eli Lilly and Company; 2015.
16. Lyxumia (lixisenatide) summary of product characteristics. Paris, France: Sanofi-Aventis Groupe; 2013.
17. Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2:289-297.
18. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384:1349-1357.
19. Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37:2159-2167.
20. Abid S, Rizvi A, Jahan F, et al. Poor glycaemic control is the major factor associated with increased frequency of gastrointestinal symptoms in patients with diabetes mellitus. J Pak Med Assoc. 2007;57:345-349.
21. Bytzer P, Talley NJ, Hammer J, Young LJ, Jones MP, Horowitz M. GI symptoms in diabetes mellitus are associated with both poor glycemic control and diabetic complications. Am J Gastroenterol. 2002;97:604-611.
22. Kim JH, Park HS, Ko SY, et al. Diabetic factors associated with gastrointestinal symptoms in patients with type 2 diabetes. World J Gastroenterol. 2010;16:1782-1787.
23. Trautmann ME, Han J, Ruggles J. Early pharmacodynamic effects of exenatide once weekly in type 2 diabetes are independent of weight loss: a pooled analysis of patient-level data. Clin Ther. 2016;38:1464-1473.
24. Jones KL, Russo A, Stevens JE, Wishart JM, Berry MK, Horowitz M. Predictors of delayed gastric emptying in diabetes. Diabetes Care. 2001;24:1264-1269.
25. Nauck MA, Wollschlager D, Werner J, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM. Diabetologia. 1996;39:1546-1553.
26. Fineman M, Flanagan S, Taylor K, et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet. 2011;50:65-74.
27. Gerich J. Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. Int J Gen Med. 2013;6:877-895.
28. Hunter K, Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012;13:33.
29. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord. 2003;27:313-318.
30. Umapathysivam MM, Lee MY, Jones KL, et al. Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. Diabetes. 2014;63:785-790.
31. Pencek R, Blickensderfer A, Li Y, Brunell SC, Chen S. Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations. Int J Clin Pract. 2012;66:1021-1032.
32. Pencek R, Blickensderfer A, Li Y, Brunell SC, Anderson PW. Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Postgrad Med. 2012;124:21-32.
33. Bytzer P, Talley NJ, Jones MP, Horowitz M. Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus. Aliment Pharmacol Ther. 2001;15:137-142.
34. Molinder H, Agreus L, Kjellstrom L, et al. How individuals with the irritable bowel syndrome describe their own symptoms before formal diagnosis. Ups J Med Sci. 2015;120:276-279.